Companies / TG Therapeutics Inc

TG Therapeutics Inc

Nasdaq: TGTXCIK 1001316NEW YORK, NYtgtherapeutics.com

Financials · FY2025

Revenue$616.29M
Net income$447.18M
Total debt$745.39M
Cash$482.57M
Diluted EPS$2.77
Shares outstanding153.1M

Ownership

153.1M shares outstanding · as of Aug 3, 2026
7.0%Insiders
Ownership
Insiders7.03%10,755,887
10%+ / strategic5.49%8,400,210
Institutions67.21%102,872,991
Public float20.28%31,039,965

% of common shares outstanding (exact, from the latest cover-page filing). Institutions are quarterly 13F snapshots; insiders reflect current officers & directors.

Insiders 7

View all →
Insider% of sharesShares
Weiss Michael SCEOCEO · Director
6.39%9,778,086
0.52%798,111
0.12%179,690
Hume DanielDirector
Lonial SagarDirector

Institutional holders 363

View all →

Activity

Jun 30, 2026View all →
InsidersInstitutions
Who's accumulating and trimming this stock (13F).
DateActorActionSecurityValueShares ΔPosition afterImpact
Q2 2026
as of
State Street Corporation
13F manager
Trim$-38.10M-694K
-8.18%
7,786,471
5.09% of shares
medium
Q1 2026
as of
Millennium Management LLC
13F manager
Trim$-18.38M-553K
-81.86%
122,587
0.08% of shares
medium
Q1 2026
as of
Two Sigma Investments, LP
13F manager
Add$16.01M+482K
+45.44%
1,542,312
1.01% of shares
medium
Q2 2025
as of
Barclays PLC
13F manager
Add$13.22M+367K
+145.18%
620,546
0.41% of shares
medium
Q1 2026
as of
Renaissance Technologies LLC
13F manager
New$11.32M+341K
340,900
0.22% of shares
medium
Q2 2026
as of
BlackRock, Inc.
13F manager
Add$11.07M+202K
+0.92%
22,050,045
14.41% of shares
medium
Q1 2026
as of
BNP Paribas Financial Markets
13F manager
Add$9.08M+273K
+39.99%
957,026
0.63% of shares
medium
Q4 2025
as of
Norges Bank
13F manager
Exit$-8.61M-218K
-100.00%
medium

5%+ ownership events

Schedule 13D / 13G
FilerStance% of classSharesDate
Vanguard Group IncPassive13G/A0
Vanguard Portfolio ManagementPassive13G8,400,210

Securities

via CUSIP / OpenFIGI
SymbolTypeMarketCUSIPFIGI
TGTX88322Q108